ApprovedFDA approval

Simtriyo (centanafadine)

Otsuka Pharmaceutical

Marketer take

A new ADHD medicine entering a large, heavily generic market, so psychiatrists, pediatricians and primary care will need clear positioning against stimulants and existing non-stimulants, and payer step edits will be a hurdle.

Sponsor company
Otsuka Pharmaceutical
Indication
To treat attention-deficit hyperactivity disorder
Therapeutic area
Psychiatry
Event
FDA approval
Date
Jul 24, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move